Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

in non-small cell lung cancer (NSCLC) at the virtual American Association for Cancer Research (AACR) annual meeting. .

Latest news

More from news
Approximately 1 fully matching, plus 830 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...

Infographics